David Liu

TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.

TL;DR: A new class of E26 transformation-specific (ETS)-fusion-negative tumors defined by mutations in epigenetic regulators, as well as alterations in pathways not previously implicated in prostate cancer, such as the spliceosome pathway are identified.

TL;DR: In this paper, the authors analyzed a clinically annotated cohort of patients with melanoma treated with anti-PD1 ICB, with whole-exome and whole-transcriptome sequencing of pre-treatment tumors.

TL;DR: This study uniformly analyzed whole-exome sequencing of 249 tumors and matched normal tissue from patients with clinically annotated outcomes to immune checkpoint therapy across multiple cancer types to examine additional tumor genomic features that contribute to selective response.

TL;DR: In breast, prostate, melanoma, and fibrosarcoma cell lines, the level of active phospho-ERK and the ERK/p38 activity ratio predict for the in vivo behavior in ∼90% of the cell lines tested, suggesting that even cells that originate in advanced cancers retain a degree of dependence on surface receptors and matrix for their proliferative signals in vivo.